Sigma Planning’s Kalaris Therapeutics KLRS Stock Holding History
Bought
Maintained
Sold
Other funds holding KLRS
SL
WT
Sigma Planning's KLRS Position: Q3 2026 in Review
Sigma Planning sold out of Kalaris Therapeutics (KLRS) in Q3 2026, closing a stake of 10,167 shares — an estimated $41.4K sold.
Sigma Planning first reported a position in KLRS in Q2 2026 and held it in 1 quarter. The position peaked at $41.4K in Q2 2026. 37 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.
- Sigma Planning reported no remaining Kalaris Therapeutics position as of Q3 2026 after selling out during the quarter.
- Sigma Planning sold 10,167 Kalaris Therapeutics shares in Q3 2026, an estimated $41.4K.
- Sigma Planning first reported a position in Kalaris Therapeutics in Q2 2026 and held it in 1 quarter.
- Sigma Planning's Kalaris Therapeutics position peaked at $41.4K in Q2 2026.
- 37 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.